Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver Paris France 11-15 April 2018 Back

Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a       Reported by Jules Levin EASL 2018 April 11-15 Paris France